Inconsistent definitions limit pathological response as a soft tissue sarcoma marker, according to a narrative review.
|Articles|September 2, 2014
Cabozantinib Fails in Phase 3
The company developing the drug, Excelis, now plans to focus it's attention on the ongoing kidney and liver cancer trials for the drug.
Advertisement
The so-called COMET-1 study enrolled 960 men with advanced prostate cancer no longer responding to treatment with the chemotherapy drug docetaxel, Johnson & Johnson's Zytiga and/or Medivation's Xtandi. The patients were randomized to treatment with cabozantinib or the steroid prednisone and followed for survival. As reported Monday, cabozantinib reduced the risk of death by 10% compared to prednisone but the difference was not statistically significant. The study failed to achieve its primary endpoint.
Complete report:
Source: The Street
Advertisement
Related to this article
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Genetic analysis finds 125 loci shared by insomnia and CRP, with Mendelian randomization favoring an effect from insomnia liability to inflammation.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Alice Hall-Partyka, JD, a partner at Crowell & Moring explains the lawsuits challenging CMS' Medicaid rule on pediatric gender care and its legal weak points.
Proinflammatory diets were tied to higher mortality in MASLD and MetALD, whereas antioxidant-rich diets tracked with better survival.
An analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.
On National Latinx AIDS Awareness Day, experts outline HIV prevention gaps in Hispanic communities and how payers can ease PrEP access.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the One Big Beautiful Bill Act
2
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
3
Medicaid Obesity GLP-1 Coverage May Offset Some Diabetes-Labeled Use
4
FAQ: How Payers Can Close HIV Prevention and PrEP Access Gaps
5